Market News (Page 33) - TendieTensor

Market News Page 33 of 283 • 7,059 articles

HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma

GlobeNewswire Inc. • Hutchmed (China) Limited

HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma

01/04/2026 07:00 PM • HUTCHMED has initiated the Phase III portion of a Phase II/III trial evaluating the combination of surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine for treatment-naïve metastatic pancreatic ductal adenocarcinoma in China. Phase II results showed the combination achieved a median PFS of 7.20 months versus 5.52 months for chemotherapy alone, representing a 50.1% reduction in progression or death risk, with a favorable overall survival trend.

USBpS - Mentioned as a client of QuoteMedia with no specific performance details
HCM - The company successfully advanced a promising combination therapy to Phase III based on Phase II data showing significant efficacy improvements (50.1% reduction in progression/death risk, higher ORR and DCR). The trial enrollment and positive clinical results support potential future regulatory approval and commercial opportunity in the large pancreatic cancer market.

#pancreatic cancer #Phase III trial #surufatinib #camrelizumab #immunotherapy #clinical trial #PDAC #first-line treatment

Could Buying Fluor Today Set You Up for Life?

The Motley Fool • Reuben Gregg Brewer

Could Buying Fluor Today Set You Up for Life?

01/04/2026 04:37 PM • Fluor, an engineering and construction company, has shifted 82% of its backlog to reimbursable contracts to improve cash flow consistency. However, the inherent cyclicality of the construction industry limits long-term reliability. While Fluor's stake in nuclear startup NuScale Power presents an interesting opportunity, the volatile NuScale stock and one-time nature of the stake sale make Fluor unsuitable for most long-term investors seeking stability.

USBpQ - Mentioned as a client of QuoteMedia with no specific performance details
FLR - While Fluor has made positive operational changes by shifting to reimbursable contracts, the inherent cyclicality of the construction industry and lack of consistent cash flow make it unsuitable for most long-term investors. The company is well-respected but volatile.

#engineering and construction #reimbursable contracts #cyclical business #nuclear energy #small modular reactors #balance sheet strengthening #volatility #long-term investment

Why This $10 Million Antero Midstream Position Isn’t Likely Just a Plain-Vanilla Yield Play

The Motley Fool • Jonathan Ponciano

Why This $10 Million Antero Midstream Position Isn’t Likely Just a Plain-Vanilla Yield Play

01/04/2026 04:31 PM • Ripple Effect Asset Management disclosed a $9.91 million position in Antero Midstream Corporation, acquiring 510,000 shares alongside put and call options. The strategic use of options alongside equity suggests the investor is hedging downside risk while maintaining upside convexity, betting on the company's strong cash generation and balance sheet improvement rather than simple yield collection.

USBpR - Mentioned as a client of QuoteMedia with no specific performance details
AM - Strong operational metrics with 10% YoY EBITDA growth, nearly doubled free cash flow after dividends, declining leverage (2.7x), and active share repurchases. The strategic options overlay by a sophisticated investor suggests conviction in the operating base and potential upside from balance sheet improvements.

#midstream energy #options strategy #hedge #cash flow #balance sheet #Appalachian Basin #natural gas #dividend yield

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

GlobeNewswire Inc. • Na

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

01/04/2026 04:00 PM • Crinetics Pharmaceuticals announced a conference call scheduled for January 5, 2026 to provide a commercialization update on PALSONIFY (paltusotine) and disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia. The company's lead product PALSONIFY is the first once-daily oral treatment approved by the FDA for acromegaly, while atumelnant is in late-stage development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome.

USBpA - Mentioned as a client of QuoteMedia with no specific performance details
CRNX - The company is announcing progress on its lead commercialized product PALSONIFY and providing results from an advanced-stage clinical trial (Phase 2 fourth cohort) for atumelnant, indicating continued pipeline advancement and commercial execution. The announcement of a pivotal Phase 3 trial initiation (mentioned in the article) further demonstrates positive momentum in drug development.

#PALSONIFY #paltusotine #atumelnant #congenital adrenal hyperplasia #Phase 2 trial #acromegaly #FDA approval #clinical development

How Trump Moved Stocks In 2025: Crypto, Drones, Health Care Sectors

Benzinga • Erica Kollmann

How Trump Moved Stocks In 2025: Crypto, Drones, Health Care Sectors

01/04/2026 03:55 PM • In 2025, Trump's administration implemented aggressive deregulation and protectionist policies across three major sectors. Crypto received institutional support through digital asset frameworks, drone manufacturers benefited from 'buy American' mandates and FAA fast-tracking, while healthcare experienced volatility from price controls and supply chain reshuffling. These policies created winners and losers across each sector.

USBpH - Mentioned as a client of QuoteMedia with no specific performance details
COIN - Benefited from Trump's pro-crypto Digital Financial Technology executive order establishing national digital asset framework and federal stablecoin regulations, driving massive inflows to crypto-linked stocks.

#Trump administration #deregulation #cryptocurrency #drone industry #healthcare pricing #executive orders #domestic manufacturing #market volatility

How Trump Moved Stocks in 2025: Nuclear, Space, Quantum Sectors

Benzinga • Erica Kollmann

How Trump Moved Stocks in 2025: Nuclear, Space, Quantum Sectors

01/04/2026 03:46 PM • President Trump's 2025 executive orders transformed nuclear, space, and quantum sectors into national priorities through regulatory streamlining and state support. Nuclear stocks surged following May orders to accelerate reactor licensing, space companies rallied from $450B to $1.3T market cap on commercial space mandates, and quantum firms benefited from research prioritization and foreign acquisition restrictions despite mid-year volatility.

USBpP - Mentioned as a client of QuoteMedia with no specific performance details
UEC - Uranium miner surged over 20% following May 23 nuclear executive orders mandating NRC licensing acceleration and advanced reactor deployment targets.

#nuclear power #space sector #quantum computing #executive orders #regulatory reform #AI data centers #small modular reactors #commercial space #lunar missions

STUBHUB DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages StubHub Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – STUB

GlobeNewswire Inc. • Rosen Law Firm

STUBHUB DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages StubHub Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – STUB

01/04/2026 02:57 PM • A class action lawsuit has been filed against StubHub Holdings, Inc. (NYSE: STUB) alleging that its September 2025 IPO registration statement was materially false and misleading. The lawsuit claims StubHub omitted disclosure of changes in vendor payment timing that significantly adversely impacted free cash flow, and that positive statements about the company's business and prospects lacked reasonable basis. Investors who purchased StubHub common stock may be entitled to compensation. The lead plaintiff deadline is January 23, 2026.

USB - Mentioned as a client of QuoteMedia with no specific performance details
STUB - The company is the subject of a securities class action lawsuit alleging material misstatements and omissions in its IPO registration statement regarding vendor payment timing and free cash flow impacts. These allegations suggest potential fraud or negligent disclosure in the company's public filings, which is inherently negative for investors.

#securities class action #IPO #registration statement #free cash flow #vendor payments #misleading disclosures #lead plaintiff deadline

RWX vs. HAUZ: Which International Real Estate ETF Is the Better Buy?

The Motley Fool • Josh Kohn-Lindquist

RWX vs. HAUZ: Which International Real Estate ETF Is the Better Buy?

01/04/2026 01:37 PM • HAUZ emerges as the superior international real estate ETF compared to RWX, offering a significantly lower expense ratio (0.10% vs 0.59%), higher dividend yield (3.91% vs 3.36%), broader diversification with 408 holdings versus 120, and better long-term performance since 2013 (3.3% annual returns vs 1.4%). While RWX showed stronger 1-year returns, HAUZ's cost efficiency and income generation make it the more attractive choice for investors seeking international property exposure.

HAUZ - HAUZ is recommended as the superior choice due to its significantly lower expense ratio (0.10% vs 0.59%), higher dividend yield, three times more holdings for better diversification, larger AUM ($932M), better 5-year performance, and superior long-term track record since 2013.

#international real estate ETF #expense ratio #dividend yield #portfolio diversification #REIT #long-term returns #cost efficiency

Firefly Aerospace Inc. Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Firefly Aerospace Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit

GlobeNewswire Inc. • Kessler Topaz Meltzer & Check, Llp

Firefly Aerospace Inc. Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Firefly Aerospace Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit

01/04/2026 12:45 PM • A securities class action lawsuit has been filed against Firefly Aerospace Inc. for alleged misconduct in its August 2025 IPO and subsequent trading period. The complaint alleges the company made false statements about demand for its Spacecraft Solutions offerings and overstated the operational readiness of its Alpha rocket program. The lead plaintiff deadline is January 12, 2026.

FLY - The company is the subject of a securities fraud class action lawsuit alleging material misstatements and omissions regarding business prospects, demand forecasts, and product viability. These allegations of fraudulent conduct in the IPO and subsequent period represent significant legal and reputational risk.

#securities fraud #class action lawsuit #IPO #Firefly Aerospace #lead plaintiff #misrepresentation #rocket program

StubHub Holdings, Inc. (STUB) Investors: January 23, 2026 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

GlobeNewswire Inc. • Kessler Topaz Meltzer & Check, Llp

StubHub Holdings, Inc. (STUB) Investors: January 23, 2026 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP

01/04/2026 12:36 PM • A securities class action lawsuit has been filed against StubHub Holdings, Inc. following its September 2025 IPO. The complaint alleges that StubHub made false and misleading statements in its offering documents by failing to disclose changes in vendor payment timing that significantly impacted free cash flow. The lead plaintiff deadline is January 23, 2026.

GIFI - Proposed sale to IES Holdings, Inc. at $12.00 per share, under investigation for potential legal concerns
STUB - The company is the subject of a securities fraud class action lawsuit alleging material misstatements and omissions in its IPO prospectus regarding vendor payment timing and free cash flow impacts. This represents significant legal and reputational risk to investors.

#securities class action #StubHub Holdings #IPO #misleading statements #free cash flow #vendor payments #lead plaintiff deadline

The Motley Fool • Justin Pope

2 Leading Tech Stocks to Buy in 2026

01/04/2026 10:34 AM • Netflix and Uber Technologies are presented as attractive investment opportunities despite recent stock declines. Netflix faces market concerns over its $82.7 billion Warner Bros. acquisition and resulting debt, but maintains strong growth prospects at a 37x P/E ratio. Uber, trading at a cheap 13x P/E, continues generating strong cash flow and revenue growth despite investor worries about autonomous vehicle competition from Tesla and Alphabet.

NFLX - Despite a 30% decline from all-time highs due to acquisition debt concerns, the stock is undervalued at 37x P/E with 24% long-term earnings growth expected. The Warner Bros. acquisition would create a powerful entertainment company with enhanced monetization opportunities.

#tech stocks #Netflix #Uber #acquisition #valuation #autonomous vehicles #streaming #ride-sharing

ROSEN, THE FIRST FILING FIRM, Encourages agilon health, inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AGL

GlobeNewswire Inc. • Rosen Law Firm

ROSEN, THE FIRST FILING FIRM, Encourages agilon health, inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AGL

01/04/2026 09:40 AM • Rosen Law Firm has filed a class action lawsuit against agilon health, inc. (NYSE: AGL) on behalf of investors who purchased securities between February 26, 2025 and August 4, 2025. The lawsuit alleges that defendants made false and misleading statements regarding 2025 guidance they knew would not be achieved, overstated financial impacts from strategic actions, and misrepresented the company's business and prospects. Investors have until March 2, 2026 to move the court if they wish to serve as lead plaintiff.

HLBAY - Proactively making a higher value acquisition proposal to potentially secure Avadel
AGL - The company is the subject of a securities class action lawsuit alleging material misstatements regarding 2025 guidance, overstatement of financial impacts from strategic actions, and false representations about business operations and prospects. These allegations indicate significant corporate governance and disclosure failures that resulted in investor losses.

#securities class action #false statements #misleading guidance #investor compensation #lead plaintiff #class certification

Could Utility Stocks Be the Next Big AI Winners?

The Motley Fool • Matt Dilallo

Could Utility Stocks Be the Next Big AI Winners?

01/04/2026 09:33 AM • Utility stocks are positioned to be major beneficiaries of the AI boom as data centers require massive amounts of electricity. NextEra Energy, Dominion Energy, and Entergy are investing billions in power generation capacity to meet surging demand from AI data center operators like Google and Meta, with expectations for strong earnings and dividend growth.

NEE - Company operates largest U.S. electric utility and has strategic partnerships with Google for nuclear energy development. Expected to grow adjusted EPS over 8% annually with increasing dividend yield.

#utility stocks #AI data centers #power demand #electricity infrastructure #earnings growth #dividend stocks

My 3 Favorite Artificial Intelligence Stocks to Buy Right Now

The Motley Fool • Patrick Sanders

My 3 Favorite Artificial Intelligence Stocks to Buy Right Now

01/04/2026 05:35 AM • The article highlights three AI stocks as investment opportunities: Palantir Technologies, which has surged 960% since January 2024 with its AI Platform securing diverse government and commercial clients; SoundHound AI, a voice recognition AI company scaling rapidly with 68% revenue growth and up 141% in 2025; and Tesla, which extends beyond EVs with significant AI investments in self-driving software and the Optimus humanoid robot project.

PLTR - Stock up 960% since Jan 2024, securing diverse high-profile clients including U.S. Navy and French intelligence agency, with strong platform integration and rapid deal pipeline expansion

#artificial intelligence #AI stocks #machine learning #voice recognition #autonomous vehicles #humanoid robots #enterprise AI #applied AI

The Market May Be Underestimating This AI Trend, and These Stocks Are Set to Benefit

The Motley Fool • Manali Pradhan, Cfa

The Market May Be Underestimating This AI Trend, and These Stocks Are Set to Benefit

01/03/2026 07:35 PM • As AI clusters scale beyond 100,000 compute nodes, networking infrastructure has become a critical bottleneck. The article highlights that investors have overlooked AI networking opportunities while focusing on GPUs. Broadcom and Coherent are positioned to benefit from surging demand for high-speed optical modules and networking components, with Broadcom reporting $20 billion in non-accelerator AI backlog and Coherent experiencing record bookings for optical connectivity equipment.

AVGO - Strong AI networking demand with $10B+ switch backlog, $20B non-accelerator AI backlog, and AI revenue expected to double year-over-year to $8.2B. Well-positioned across both accelerator and networking portfolios for AI infrastructure buildout.

#AI networking #optical modules #800G and 1.6T interconnects #data center infrastructure #hyperscalers #AI backlog #silicon photonics

JYD DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Jayud Global Logistics Ltd. Investors to Secure Counsel Before Important January 20 Deadline in Securities Class Action - JYD

GlobeNewswire Inc. • Rosen Law Firm

JYD DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Jayud Global Logistics Ltd. Investors to Secure Counsel Before Important January 20 Deadline in Securities Class Action - JYD

01/03/2026 04:49 PM • Rosen Law Firm announces a securities class action lawsuit against Jayud Global Logistics Ltd. (NASDAQ: JYD) for investors who purchased securities between April 21, 2023 and April 30, 2025. The lawsuit alleges that defendants made materially false statements and failed to disclose a fraudulent stock promotion scheme involving social media misinformation, coordinated share dumping by insiders using offshore accounts, and artificial trading activity. The lead plaintiff deadline is January 20, 2026.

JYD - The company is the subject of a securities class action lawsuit alleging fraudulent stock promotion schemes, insider share dumping through offshore accounts, false public statements, and misleading risk disclosures. These serious allegations of fraud and market manipulation indicate significant legal and reputational risks for investors.

#securities class action #Jayud Global Logistics #fraudulent stock promotion #insider trading #misleading statements #lead plaintiff deadline #investor compensation

A Sionna Therapeutics (SION) Insider Sold 33,000 Shares for $1.5 Million

The Motley Fool • Cory Renauer

A Sionna Therapeutics (SION) Insider Sold 33,000 Shares for $1.5 Million

01/03/2026 02:35 PM • OrbiMed Advisors sold 33,356 shares of Sionna Therapeutics for approximately $1.5 million on December 24, 2025, reducing its indirect holdings to 3.56 million shares. The sale represents a routine disposition as part of structured block sales, not an indication of insider concern. Sionna, a clinical-stage biotech focused on cystic fibrosis treatments, reported positive phase 1 results in June and began phase 2 trials in October, with top-line results expected mid-2026.

SION - The insider sale is characterized as routine income supplementation rather than a sign of distress, with the seller retaining substantial holdings (3.56M shares). The company shows clinical progress with positive phase 1 results and ongoing phase 2 trials, but remains pre-commercial with significant development risk ahead. The neutral sentiment reflects both positive clinical progress and the inherent uncertainty of clinical-stage biotech development.

#insider sale #cystic fibrosis #clinical-stage biotech #CFTR protein #phase 2 trial #OrbiMed Advisors #rare disease

Exor-Ferrari Family Press Release - Shareholders' Agreement

GlobeNewswire Inc. • Na

Exor-Ferrari Family Press Release - Shareholders' Agreement

01/03/2026 12:47 PM • Exor N.V. and Piero Ferrari have renewed their shareholders' agreement on Ferrari N.V., extending their alignment and commitment through January 4, 2029, with automatic renewal provisions. The agreement includes consultation arrangements for coordinating positions on shareholder matters and reciprocal rights of first offer for share transfers.

NVDA - Referenced as an example stock for Bitget's synthetic futures contracts
RACE - The renewal of the shareholders' agreement demonstrates continued commitment and alignment between major stakeholders, providing stability and governance clarity for the company.

#shareholders' agreement #Ferrari #Exor #Piero Ferrari #share transfer #renewal

Another PR Announces New Tech Startups to Watch at CES 2026

GlobeNewswire Inc. • Another Pr

Another PR Announces New Tech Startups to Watch at CES 2026

01/03/2026 12:46 PM • As CES 2026 approaches, Another PR has curated a list of emerging technology startups focusing on practical, energy-efficient, and human-centered solutions. Featured companies span artificial intelligence, digital health, accessibility, and connected systems, reflecting broader industry trends toward embedded AI, on-device computing, and personalized health technology.

TTMZF - Addressing significant healthcare challenges in medication management with a modern, secure system that supports patient independence and caregiver visibility, reflecting human-centered healthcare innovation.

#CES 2026 #technology startups #artificial intelligence #edge AI #digital health #accessibility #wearable technology #smart home #energy-efficient computing

INSP DEADLINE MONDAY: ROSEN, A LONGSTANDING LAW FIRM, Encourages Inspire Medical Systems, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important January 5 Deadline in Securities Class Action - INSP

GlobeNewswire Inc. • Rosen Law Firm

INSP DEADLINE MONDAY: ROSEN, A LONGSTANDING LAW FIRM, Encourages Inspire Medical Systems, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important January 5 Deadline in Securities Class Action - INSP

01/03/2026 11:00 AM • Rosen Law Firm announces a securities class action lawsuit against Inspire Medical Systems, Inc. (NYSE: INSP) for investors who purchased stock between August 6, 2024 and August 4, 2025. The lawsuit alleges that defendants misrepresented key facts about the Inspire V sleep apnea device, including actual market demand and launch readiness. The lead plaintiff deadline is January 5, 2026.

INSP - The company is the subject of a securities class action lawsuit alleging material misrepresentations and non-disclosures regarding the Inspire V device's market demand and launch readiness, resulting in investor losses.

#securities class action #Inspire Medical Systems #Inspire V device #misrepresentation #lead plaintiff deadline #investor losses

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages agilon health, inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AGL

GlobeNewswire Inc. • Rosen Law Firm

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages agilon health, inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AGL

01/03/2026 10:52 AM • Rosen Law Firm has filed a class action lawsuit against Agilon Health, Inc. (NYSE: AGL) on behalf of investors who purchased securities between February 26, 2025 and August 4, 2025. The lawsuit alleges that defendants made false and misleading statements regarding 2025 guidance they knew would not be achieved, overstated financial impacts from strategic actions, and misrepresented the company's business and prospects. Investors must move the court by March 2, 2026 to serve as lead plaintiff.

TSLA - Referenced as an example stock for Bitget's synthetic futures contracts
AGL - The company is the subject of a securities class action lawsuit alleging material misstatements regarding 2025 guidance, overstatement of financial impacts from strategic actions, and false representations about business operations and prospects. These allegations indicate significant corporate governance and disclosure failures that resulted in investor losses.

#securities class action #false statements #misleading guidance #investor compensation #lead plaintiff deadline

STUB DEADLINE REMINDER: Faruqi & Faruqi Reminds StubHub Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 23, 2026

GlobeNewswire Inc. • Faruqi & Faruqi, Llp

STUB DEADLINE REMINDER: Faruqi & Faruqi Reminds StubHub Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 23, 2026

01/03/2026 07:50 AM • A securities class action has been filed against StubHub Holdings, Inc. alleging that its IPO registration statement was materially false and misleading. The complaint claims the company failed to disclose adverse changes in vendor payment timing that significantly impacted free cash flow. Following the November 13, 2025 earnings announcement revealing a 143% decline in quarterly free cash flow, StubHub's stock fell 20.9% and has since declined nearly 56% from its $23.50 IPO price. The deadline to seek lead plaintiff status is January 23, 2026.

ASX - Provides comprehensive organic substrate design and manufacturing services, including advanced packaging solutions
STUB - The company is the subject of a securities class action alleging material misrepresentations in its IPO registration statement regarding free cash flow and vendor payment timing. The stock has declined 56% from its IPO price following disappointing earnings results, indicating significant investor losses and loss of confidence.

#class action lawsuit #securities fraud #IPO #free cash flow #vendor payments #stock decline #lead plaintiff deadline

DEADLINE REMINDER: Faruqi & Faruqi, LLP Reminds Sprouts Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 26, 2026

GlobeNewswire Inc. • Faruqi & Faruqi, Llp

DEADLINE REMINDER: Faruqi & Faruqi, LLP Reminds Sprouts Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 26, 2026

01/03/2026 07:47 AM • A federal securities class action has been filed against Sprouts Farmers Market for allegedly making false and misleading statements about the company's growth potential while concealing material adverse facts. On October 29, 2025, Sprouts reported a 4.3% decrease in comparable store sales growth and reduced full-year guidance from 7.5%-9% to 7%, causing the stock to fall $22.64 per share. The deadline to seek lead plaintiff status is January 26, 2026.

KYOCY - Major supplier of advanced organic packaging substrates for high-performance semiconductors with innovative product showcases
SFM - The company is facing a federal securities class action alleging false and misleading statements about growth potential. Additionally, Sprouts reported disappointing Q3 results with a 4.3% decline in comparable store sales growth, significantly reduced forward guidance, and a substantial stock price decline of $22.64 per share following the announcement.

#class action lawsuit #securities fraud #misleading statements #comparable store sales decline #guidance reduction #lead plaintiff deadline

DEADLINE REMINDER: Faruqi & Faruqi, LLP Reminds SLM Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 17, 2026

GlobeNewswire Inc. • Faruqi & Faruqi, Llp

DEADLINE REMINDER: Faruqi & Faruqi, LLP Reminds SLM Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 17, 2026

01/03/2026 07:43 AM • A federal securities class action has been filed against SLM Corporation alleging that the company and its executives made false and misleading statements regarding delinquency rates and the effectiveness of loan modification programs. The complaint claims SLM concealed a significant increase in early-stage delinquencies, contradicting executive assurances about normal seasonal trends. Following a TD Cowen report on August 14, 2025 that revealed delinquencies were up 49 basis points month-over-month, SLM's stock fell 8.09%. The deadline to seek lead plaintiff status is February 17, 2026.

SLM - The company is the subject of a federal securities class action alleging material misstatements about delinquency rates and loan modification program effectiveness. Executives allegedly made false assurances about seasonal trends that were contradicted by independent analysis, resulting in an 8.09% stock price decline.

#class action lawsuit #securities fraud #delinquencies #loan modification #misleading statements #lead plaintiff deadline

INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT

GlobeNewswire Inc. • Faruqi & Faruqi, Llp

INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT

01/03/2026 07:41 AM • Rezolute, Inc. shares collapsed approximately 85-90% on December 11, 2025, after the company's Phase 3 sunRIZE clinical trial for its lead drug candidate ersodetug failed to meet primary and key secondary endpoints in treating congenital hyperinsulinism. The stock dropped from around $10.94 to an intraday low near $0.90, triggering Nasdaq volatility halts.

PRMB - Limited information provided, only mentioned in passing without specific details
RZLT - The company experienced a catastrophic stock price decline of 85-90% due to its lead drug candidate failing to meet primary and secondary endpoints in a Phase 3 clinical trial, representing a major setback for the company's pipeline and investor confidence.

#clinical trial failure #Phase 3 trial #stock collapse #congenital hyperinsulinism #ersodetug #securities litigation